Profile data is unavailable for this security.
About the company
Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment develops, manufactures, and distributes rigid bracing products, orthopedic soft goods, vascular systems and compression garments, and hot and cold therapy products and offers recovery sciences products in the clinical rehabilitation and sports medicine markets, such as bone growth stimulators and electrical stimulators used for pain management. The Reconstructive segment develops, manufactures, and markets a variety of knee, hip, shoulder, elbow, foot, ankle, and finger implant products and surgical productivity tools. It also provides Novastep, a minimally invasive surgery (MIS) foot and ankle solutions.
- Revenue in USD (TTM)1.91bn
- Net income in USD-107.11m
- Incorporated1998
- Employees6.55k
- LocationEnovis Corp2711 CENTERVILLE ROAD, SUITE 400WILMINGTON 19808United StatesUSA
- Phone+1 (302) 252-9160
- Fax+1 (301) 323-9001
- Websitehttps://www.enovis.com/
More ▼
Mergers & acquisitions
| Acquired company | ENOV:NYQ since announced | Transaction value |
|---|---|---|
| Limacorporate SpA | -15.45% | 852.16m |
Data delayed at least 15 minutes, as of Sep 21 2024 00:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novocure Ltd | 549.96m | -168.70m | 1.89bn | 1.45k | -- | 5.21 | -- | 3.43 | -1.58 | -1.58 | 5.13 | 3.35 | 0.4639 | 3.62 | 8.11 | 378,502.40 | -14.23 | -7.74 | -16.44 | -8.95 | 75.83 | 77.22 | -30.67 | -14.69 | 6.22 | -- | 0.6437 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Patterson Companies, Inc. | 6.53bn | 168.41m | 1.90bn | 7.60k | 11.80 | 2.00 | 7.38 | 0.2913 | 1.83 | 1.83 | 71.22 | 10.80 | 2.27 | 5.86 | 15.35 | 859,640.70 | 5.84 | 1.13 | 10.15 | 1.81 | 21.03 | 20.98 | 2.57 | 0.5157 | 0.6723 | 7.91 | 0.4474 | 304.75 | 1.50 | 3.34 | -10.42 | 18.10 | 2.17 | 0.00 |
| Premier Inc | 1.35bn | 119.54m | 1.99bn | 2.90k | 19.17 | 1.06 | 8.45 | 1.48 | 1.04 | 1.04 | 11.78 | 18.68 | 0.3976 | 5.85 | 3.07 | 464,262.40 | 3.15 | 7.08 | 4.10 | 8.95 | 65.96 | 61.29 | 7.93 | 16.05 | 0.8951 | -- | 0.2775 | 27.32 | 0.7684 | 2.03 | -31.70 | -11.93 | -2.76 | -- |
| LeMaitre Vascular Inc | 205.62m | 37.68m | 2.02bn | 614.00 | 53.90 | 6.33 | 42.75 | 9.83 | 1.67 | 1.67 | 9.11 | 14.22 | 0.5964 | 1.13 | 7.19 | 334,887.60 | 10.93 | 9.02 | 11.81 | 9.93 | 67.70 | 65.83 | 18.32 | 15.45 | 5.86 | -- | 0.00 | 40.41 | 19.69 | 12.88 | 45.89 | 5.96 | 18.93 | 15.51 |
| Omnicell Inc | 1.08bn | -20.76m | 2.05bn | 3.65k | -- | 1.71 | 31.75 | 1.90 | -0.4558 | -0.4558 | 23.63 | 26.15 | 0.4818 | 5.64 | 4.20 | 296,013.40 | -0.9258 | 1.73 | -1.12 | 2.25 | 41.63 | 46.69 | -1.92 | 2.92 | 2.22 | -- | 0.322 | 0.00 | -11.48 | 7.82 | -460.68 | -- | 0.235 | -- |
| Rxsight Inc | 115.18m | -36.77m | 2.10bn | 374.00 | -- | 7.63 | -- | 18.25 | -1.01 | -1.01 | 3.14 | 6.95 | 0.46 | 2.08 | 5.90 | 307,962.60 | -14.69 | -- | -15.83 | -- | 66.26 | -- | -31.93 | -- | 13.34 | -- | 0.0005 | -- | 81.77 | -- | 27.19 | -- | -- | -- |
| Irhythm Technologies Inc | 537.09m | -131.59m | 2.19bn | 2.00k | -- | 22.03 | -- | 4.07 | -4.26 | -4.26 | 17.40 | 3.18 | 0.7965 | 11.79 | 7.86 | 268,545.50 | -19.51 | -21.92 | -22.66 | -26.77 | 67.19 | 69.39 | -24.50 | -25.75 | 6.76 | -13.78 | 0.8667 | -- | 19.90 | 27.32 | -6.24 | -- | 50.82 | -- |
| Conmed Corp | 1.28bn | 98.59m | 2.32bn | 4.00k | 23.86 | 2.63 | 13.60 | 1.82 | 3.15 | 3.15 | 40.81 | 28.61 | 0.5538 | 1.75 | 5.45 | 318,998.30 | 4.28 | 0.8972 | 4.94 | 1.02 | 55.32 | 54.95 | 7.73 | 1.65 | 1.13 | 4.20 | 0.5228 | 139.16 | 19.06 | 7.68 | 179.99 | 10.04 | 2.89 | 0.00 |
| Enovis Corp | 1.91bn | -107.11m | 2.44bn | 6.55k | -- | 0.7291 | 16.87 | 1.27 | -1.96 | -1.65 | 35.01 | 59.90 | 0.3872 | 1.53 | 5.52 | 292,209.20 | -2.16 | -0.3569 | -2.37 | -0.41 | 57.30 | 48.19 | -5.57 | -1.06 | 1.08 | 0.836 | 0.2902 | -- | 9.22 | -4.89 | -40.29 | -- | 11.91 | -- |
| Myriad Genetics, Inc. | 802.20m | -155.20m | 2.51bn | 2.70k | -- | 3.39 | -- | 3.13 | -1.80 | -1.80 | 9.20 | 8.15 | 0.7061 | 10.21 | 6.99 | 297,111.10 | -13.66 | -- | -16.32 | -- | 69.06 | -- | -19.35 | -- | 1.78 | -113.89 | 0.0498 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
| Inari Medical Inc | 547.47m | -57.05m | 2.55bn | 1.30k | -- | 5.99 | -- | 4.65 | -0.9838 | -0.9838 | 9.43 | 7.29 | 0.9141 | 1.59 | 7.56 | 421,133.80 | -9.53 | -0.5941 | -11.39 | -0.6696 | 87.15 | 89.06 | -10.42 | -0.6295 | 1.45 | -- | 0.00 | -- | 28.73 | 135.40 | 94.41 | -- | 52.46 | -- |
| 10X Genomics Inc | 631.73m | -239.78m | 2.73bn | 1.26k | -- | 3.77 | -- | 4.33 | -2.02 | -2.02 | 5.31 | 6.01 | 0.6583 | 2.59 | 7.06 | 501,773.60 | -24.99 | -25.52 | -28.04 | -29.05 | 64.70 | 75.88 | -37.96 | -48.53 | 4.42 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| UFP Technologies Inc | 417.47m | 49.55m | 2.75bn | 3.09k | 55.91 | 8.87 | 44.81 | 6.59 | 6.41 | 6.41 | 54.02 | 40.42 | 1.02 | 4.26 | 6.68 | 134,971.50 | 12.08 | 9.69 | 13.85 | 10.95 | 28.02 | 26.33 | 11.87 | 10.14 | 1.63 | 21.63 | 0.1024 | 0.00 | 13.08 | 16.00 | 7.50 | 25.71 | 14.08 | -- |
| LivaNova PLC | 1.21bn | -16.59m | 2.76bn | 2.90k | -- | 2.22 | 91.88 | 2.28 | -0.3133 | -0.3133 | 22.29 | 22.88 | 0.5046 | 2.52 | 6.26 | 417,149.00 | -0.6876 | -6.01 | -0.7843 | -7.42 | 67.64 | 66.99 | -1.36 | -13.56 | 2.94 | 2.19 | 0.3347 | -- | 12.89 | 0.8278 | 120.34 | -- | -1.64 | -- |
| Tandem Diabetes Care Inc | 796.00m | -136.49m | 2.92bn | 2.40k | -- | 12.49 | -- | 3.67 | -2.09 | -2.09 | 12.21 | 3.57 | 0.8449 | 2.62 | 8.09 | 331,667.50 | -14.49 | -10.08 | -18.58 | -12.23 | 49.06 | 51.77 | -17.15 | -11.59 | 2.38 | -- | 0.598 | -- | -6.68 | 32.39 | -135.33 | -- | 76.81 | -- |
| Quidelortho Corp | 2.83bn | -1.86bn | 3.05bn | 7.10k | -- | 0.9599 | -- | 1.08 | -27.79 | -27.79 | 42.35 | 47.30 | 0.372 | 2.58 | 9.15 | 399,239.40 | -24.40 | 11.34 | -27.51 | 12.91 | 47.89 | 62.71 | -65.60 | 20.93 | 0.7929 | 0.7895 | 0.4469 | 0.00 | -8.21 | 41.83 | -101.84 | -- | 45.87 | -- |
Data as of Sep 21 2024. Currency figures normalised to Enovis Corp's reporting currency: US Dollar USD
57.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Investment Management, Inc.as of 30 Jun 2024 | 6.64m | 11.89% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 5.28m | 9.45% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 4.53m | 8.12% |
| Dimensional Fund Advisors LPas of 30 Jun 2024 | 3.04m | 5.44% |
| Diamond Hill Capital Management, Inc.as of 30 Jun 2024 | 2.79m | 4.99% |
| Davenport & Co. LLCas of 30 Jun 2024 | 2.32m | 4.15% |
| Royce & Associates LPas of 30 Jun 2024 | 2.06m | 3.68% |
| Millennium Management LLCas of 30 Jun 2024 | 1.92m | 3.44% |
| Thrivent Asset Management LLCas of 30 Jun 2024 | 1.82m | 3.26% |
| Channing Capital Management LLCas of 30 Jun 2024 | 1.71m | 3.07% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
